MX2021009423A - Formas cristalinas de un inhibidor de la janocinasa 2 (jak2). - Google Patents

Formas cristalinas de un inhibidor de la janocinasa 2 (jak2).

Info

Publication number
MX2021009423A
MX2021009423A MX2021009423A MX2021009423A MX2021009423A MX 2021009423 A MX2021009423 A MX 2021009423A MX 2021009423 A MX2021009423 A MX 2021009423A MX 2021009423 A MX2021009423 A MX 2021009423A MX 2021009423 A MX2021009423 A MX 2021009423A
Authority
MX
Mexico
Prior art keywords
crystalline forms
jak2 inhibitor
jak2
inhibitor
compositions
Prior art date
Application number
MX2021009423A
Other languages
English (en)
Spanish (es)
Inventor
Pascal Billot
Benoit Robert
Original Assignee
Impact Biomedicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Impact Biomedicines Inc filed Critical Impact Biomedicines Inc
Publication of MX2021009423A publication Critical patent/MX2021009423A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2021009423A 2019-02-12 2020-02-11 Formas cristalinas de un inhibidor de la janocinasa 2 (jak2). MX2021009423A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1902018A FR3092581A1 (fr) 2019-02-12 2019-02-12 Formes cristallines d'un inhibiteur de jak2
PCT/US2020/017764 WO2020167844A1 (en) 2019-02-12 2020-02-11 Crystalline forms of a jak2 inhibitor

Publications (1)

Publication Number Publication Date
MX2021009423A true MX2021009423A (es) 2021-11-17

Family

ID=68281482

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021009423A MX2021009423A (es) 2019-02-12 2020-02-11 Formas cristalinas de un inhibidor de la janocinasa 2 (jak2).

Country Status (13)

Country Link
US (1) US20220332706A1 (cg-RX-API-DMAC7.html)
EP (1) EP3927704A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022520083A (cg-RX-API-DMAC7.html)
KR (1) KR20210148110A (cg-RX-API-DMAC7.html)
CN (1) CN114026088A (cg-RX-API-DMAC7.html)
AU (1) AU2020221796A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021015318A2 (cg-RX-API-DMAC7.html)
EA (1) EA202192237A1 (cg-RX-API-DMAC7.html)
FR (1) FR3092581A1 (cg-RX-API-DMAC7.html)
IL (1) IL285427A (cg-RX-API-DMAC7.html)
MX (1) MX2021009423A (cg-RX-API-DMAC7.html)
SG (1) SG11202108607QA (cg-RX-API-DMAC7.html)
WO (1) WO2020167844A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY209349A (en) 2018-09-25 2025-07-03 Impact Biomedicines Inc Methods of treating myeloproliferative disorders
US12559463B2 (en) 2019-02-12 2026-02-24 Impact Biomedicines Inc. Crystalline forms of a JAK2 inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007053452A1 (en) * 2005-11-01 2007-05-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
AU2010363329A1 (en) * 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
WO2013013195A1 (en) * 2011-07-21 2013-01-24 Sanofi Compositions and methods for treating polycythemia vera and essential thrombocythemia
JP2020504711A (ja) * 2016-12-21 2020-02-13 バイオセリックス, インコーポレイテッド タンパク質を標的とすることにおいて使用するための、チエノピロール誘導体、その組成物、方法、および使用

Also Published As

Publication number Publication date
EP3927704A1 (en) 2021-12-29
SG11202108607QA (en) 2021-09-29
AU2020221796A1 (en) 2021-08-12
JP2022520083A (ja) 2022-03-28
US20220332706A1 (en) 2022-10-20
FR3092581A1 (fr) 2020-08-14
KR20210148110A (ko) 2021-12-07
BR112021015318A2 (pt) 2021-10-05
WO2020167844A1 (en) 2020-08-20
IL285427A (en) 2021-09-30
EA202192237A1 (ru) 2021-12-14
EP3927704A4 (en) 2022-12-28
CN114026088A (zh) 2022-02-08
JP2025032217A (ja) 2025-03-11

Similar Documents

Publication Publication Date Title
MX2022007576A (es) Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
MX2021006154A (es) Degradadores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
CL2021003373A1 (es) Nuevos inhibidores de egfr
CO2022002759A2 (es) Antagonistas de hpk1 y sus usos
MX2021014443A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
MX2023004593A (es) Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos.
MX2018010427A (es) Formas solidas de un inhibidor de tienopirimidindiona acetil coa carboxilasa y metodos para su produccion.
NI202100018A (es) Moduladores de la expresión de pnpla3
ECSP16067303A (es) Heteroarilos y usos de estos
CR20190471A (es) Moduladores de la expresión de pcsk9
EA201792604A1 (ru) Ингибиторы аутотаксина и их применения
MX2020013630A (es) Analogos de rapamicina y usos de los mismos.
MX386146B (es) Métodos para tratar esclerosis múltiple usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton.
JOP20200291A1 (ar) معدلات التعبير عن apol1
MX2022002446A (es) Compuestos de pirrolopirimidina inhibidores de perk.
MX2021003450A (es) Metodos para tratar trastornos mieloproliferativos.
UY38352A (es) Inhibidores de integrina alfavbeta6
BR112022005895A2 (pt) Inibidores de aldose redutase para tratamento de deficiência de fosfomanomutase 2
CL2020000217A1 (es) Inhibidores de ror gamma.
MX2020012990A (es) Formulaciones de tegavivint y compuestos relacionados.
CO2020006542A2 (es) Profármacos de creatina, composiciones y métodos de uso de estos
PH12018501943A1 (en) Pharmaceutical compositions for the treatment of cancer
ECSP22046595A (es) Procesos e intermediario para la preparaci?n de oxetan-2-ilmetanamina
EA202192237A1 (ru) Кристаллические формы ингибитора jak2
ZA202106519B (en) Caspase inhibitors and methods of use thereof